205 related articles for article (PubMed ID: 19644994)
1. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.
Fletcher S; Singh J; Zhang X; Yue P; Page BD; Sharmeen S; Shahani VM; Zhao W; Schimmer AD; Turkson J; Gunning PT
Chembiochem; 2009 Aug; 10(12):1959-64. PubMed ID: 19644994
[No Abstract] [Full Text] [Related]
2. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
Page BD; Fletcher S; Yue P; Li Z; Zhang X; Sharmeen S; Datti A; Wrana JL; Trudel S; Schimmer AD; Turkson J; Gunning PT
Bioorg Med Chem Lett; 2011 Sep; 21(18):5605-9. PubMed ID: 21788134
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.
Fletcher S; Page BD; Zhang X; Yue P; Li ZH; Sharmeen S; Singh J; Zhao W; Schimmer AD; Trudel S; Turkson J; Gunning PT
ChemMedChem; 2011 Aug; 6(8):1459-70. PubMed ID: 21618433
[TBL] [Abstract][Full Text] [Related]
4. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
5. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
[TBL] [Abstract][Full Text] [Related]
6. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
7. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
8. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.
Cardoso AA; Jiang Y; Luo M; Reed AM; Shahda S; He Y; Maitra A; Kelley MR; Fishel ML
PLoS One; 2012; 7(10):e47462. PubMed ID: 23094050
[TBL] [Abstract][Full Text] [Related]
9. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
[TBL] [Abstract][Full Text] [Related]
10. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
11. STAT3 activation in monocytes accelerates liver cancer progression.
Wu WY; Li J; Wu ZS; Zhang CL; Meng XL
BMC Cancer; 2011 Dec; 11():506. PubMed ID: 22136659
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.
Ball DP; Lewis AM; Williams D; Resetca D; Wilson DJ; Gunning PT
Oncotarget; 2016 Apr; 7(15):20669-79. PubMed ID: 26942696
[TBL] [Abstract][Full Text] [Related]
13. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
14. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.
Deng XS; Wang S; Deng A; Liu B; Edgerton SM; Lind SE; Wahdan-Alaswad R; Thor AD
Cell Cycle; 2012 Jan; 11(2):367-76. PubMed ID: 22189713
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity of Water-Soluble Olsalazine-PAMAM-Dendrimer-Salicylic Acid-Conjugates.
Cortez-Maya S; Pedro-Hernández LD; Martínez-Klimova E; Ramírez-Ápan T; Martínez-García M
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31412571
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and
Oleksak P; Psotka M; Vancurova M; Sapega O; Bieblova J; Reinis M; Rysanek D; Mikyskova R; Chalupova K; Malinak D; Svobodova J; Andrys R; Rehulkova H; Skopek V; Ngoc Lam P; Bartek J; Hodny Z; Musilek K
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):410-424. PubMed ID: 33440995
[TBL] [Abstract][Full Text] [Related]
18. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders.
Gunning PT; Glenn MP; Siddiquee KA; Katt WP; Masson E; Sebti SM; Turkson J; Hamilton AD
Chembiochem; 2008 Nov; 9(17):2800-3. PubMed ID: 19006150
[No Abstract] [Full Text] [Related]
20. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
